Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
December 22, 2014 at 08:31 AM EST
Cerus Corporation (NASDAQ: CERS) announced today that its Phase 2 clinical trial of red blood cells treated with the INTERCEPT Blood ...
